The laboratory is capable of handling highly potent compounds with an OEL as low as 1 ng/m3, and is already available to customers
CordenPharma has announced the completion of a highly potent API laboratory in its Boulder, Colorado facility.
CordenPharma says it has extensive experience and capabilities in the development and manufacturing of highly potent APIs from clinical to commercial scale. “Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” said Jason Bertola, Director of CordenPharma’s Global Highly Potent & Oncology Platform.